JLL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Jones Lang LaSalle Inc (JLL) is not a strong buy at the moment given the investor's beginner level, long-term strategy, and available capital. While analysts are optimistic about the stock's future, the current technical indicators, options sentiment, and recent negative news sentiment suggest caution. The stock is oversold, but there is no immediate signal or catalyst to suggest a strong rebound in the short term. A hold is recommended until more favorable conditions emerge.
The stock is currently oversold with an RSI of 12.271, indicating potential for a rebound. However, the MACD histogram is negative and expanding, suggesting bearish momentum. The stock is trading near its key support level of 279.318, with resistance levels at 317.875 and 356.433. Moving averages are converging, indicating a lack of clear trend direction.
Analysts have raised price targets significantly, with UBS setting a target of $410 and Goldman Sachs at $407, both maintaining a Buy rating.
JLL's Q3 2025 financials showed strong growth, with revenue up 10.93% YoY and net income up 43.65% YoY.
JLL's involvement in high-profile projects like The Crescent highlights its market strength.
The stock has declined 14% year-to-date despite positive earnings revisions.
Concerns about AI's disruptive potential in the real estate services sector have negatively impacted sentiment.
Options data shows bearish sentiment with a high put-call volume ratio and elevated implied volatility.
In Q3 2025, JLL reported strong financial growth: revenue increased by 10.93% YoY to $6.51 billion, net income rose by 43.65% YoY to $222.8 million, and EPS grew by 44.06% YoY to 4.61. This indicates robust operational performance and profitability.
Analysts are optimistic about JLL's long-term prospects. UBS raised the price target to $410, and Goldman Sachs to $407, both maintaining Buy ratings. Keefe Bruyette also raised its target to $405, citing a recovery phase in the commercial real estate cycle. However, Barclays initiated coverage with an Equal Weight rating and a $351 price target, reflecting some caution.
